FILE:JPM/JPM-8K-20080925170800.txt.gz
EVENTS:	Financial Statements and Exhibits
TEXT:
ITEM: Financial Statements and Exhibits
 
 
 
 
 
 
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 
 
 
 
 
 
 
 
The following Exhibits are incorporated by reference into the Registration Statement on Form S-3ASR (333-130051) of JPMorgan Chase & Co. (the Registrant) as exhibits thereto and are filed as part of this Current Report.
 
 
 
 
 
 
 
 
2
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Dated: September 25, 2008
 
 
 
 
 
 
 
 
 
3
 
 
 
 
 
 
 
 
 
 
 
4
 

 
Exhibit 8.1
 
 
 
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 1560 dated September 24, 2008 relating to $3,655,000 Floating Rate Notes Linked to the Consumer Price Index due September 30, 2013 (the Pricing Supplement) to product supplement no. 3-II dated February 13, 2006 relating to Floating Rate Notes Linked to the Consumer Price Index (the Product Supplement) to a prospectus supplement dated December 1, 2005 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Tax Treatment in the Pricing Supplement, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading Selected Purchase Considerations  Tax Treatment in the Pricing Supplement.  By such consent we do not concede that we are an expert for the purposes of the Act.

 
Exhibit 8.2
 
 
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. dated September 24, 2008 relating to $6,055,000 Buffered Return Enhanced Notes Linked to the S&P 500 Index due March 31, 2010  (the Pricing Supplement) to product supplement no. 39-XII dated September 3, 2008 relating to Return Enhanced Notes Linked to a Weighted Basket Consisting of One or More of the S&P 500 Index, the S&P MidCap 400 Index, the S&P BRIC 40 Index, the Nikkei 225 Index, the Dow Jones EURO STOXX 50 Index, the Dow Jones U.S. Real Estate Index, the Dow Jones  AIG Commodity IndexSM, the FTSE 100 Index, the MSCI EAFE Index, the MSCI World IndexSM, the NASDAQ-100 Index, the Russell 1000 Growth Index, the Russell 1000 Value Index, the Russell 2000 Index, the iShares Dow Jones U.S. Real Estate Index Fund, the iShares MSCI Emerging Markets Index Fund, the PowerShares Water Resources Portfolio, the SPDR S&P Homebuilders ETF, the Financial Select Sector SPDR Fund and the Vanguard Emerging Markets ETF  (the Product Supplement) to a prospectus supplement dated October 12, 2006 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
1561
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Capital Gains Tax Treatment in the Pricing Supplement, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Capital Gains Tax Treatment in the Pricing Supplement.  By such consent we do not concede that we are an expert for the purposes of the Act.

 
Exhibit 8.3
 
 
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. dated September 24, 2008 relating to $3,036,000 Buffered Return Enhanced Notes Linked to the S&P 500 Index due March 31, 2010  (the Pricing Supplement) to product supplement no. 39-XII dated September 3, 2008 relating to Return Enhanced Notes Linked to a Weighted Basket Consisting of One or More of the S&P 500 Index, the S&P MidCap 400 Index, the S&P BRIC 40 Index, the Nikkei 225 Index, the Dow Jones EURO STOXX 50 Index, the Dow Jones U.S. Real Estate Index, the Dow Jones  AIG Commodity IndexSM, the FTSE 100 Index, the MSCI EAFE Index, the MSCI World IndexSM, the NASDAQ-100 Index, the Russell 1000 Growth Index, the Russell 1000 Value Index, the Russell 2000 Index, the iShares Dow Jones U.S. Real Estate Index Fund, the iShares MSCI Emerging Markets Index Fund, the PowerShares Water Resources Portfolio, the SPDR S&P Homebuilders ETF, the Financial Select Sector SPDR Fund and the Vanguard Emerging Markets ETF  (the Product Supplement) to a prospectus supplement dated October 12, 2006 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
1562
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Capital Gains Tax Treatment in the Pricing Supplement, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Capital Gains Tax Treatment in the Pricing Supplement.  By such consent we do not concede that we are an expert for the purposes of the Act.


